𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vivo measurement of plaque burden in a mouse model of Alzheimer's disease

✍ Scribed by Arijitt Borthakur; Tamar Gur; Andrew J. Wheaton; Matthew Corbo; John Q. Trojanowski; Virginia M.-Y. Lee; Ravinder Reddy

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
486 KB
Volume
24
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Purpose

To demonstrate an MRI method for directly visualizing amyloid‐β (Aβ) plaques in the APP/PS1 transgenic (tg) mouse brain in vivo, and show that T~1ρ~ relaxation rate increases progressively with Alzheimer's disease (AD)‐related pathology in the tg mouse brain.

Materials and Methods

We obtained in vivo MR images of a mouse model of AD (APP/PS1) that overexpresses human amyloid precursor protein, and measured T~1ρ~ via quantitative relaxometric maps.

Results

A significant decrease in T~1ρ~ was observed in the cortex and hippocampus of 12‐ and 18‐month‐old animals compared to their age‐matched controls. There was also a correlation between changes in T~1ρ~ and the age of the animals.

Conclusion

T~1ρ~ relaxometry may be a sensitive method for noninvasively determining AD‐related pathology in APP/PS1 mice. J. Magn. Reson. Imaging 2006. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

MRI assessment of neuropathology in a tr
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease
✍ Joseph A. Helpern; Sang-Pil Lee; Maria F. Falangola; Victor V. Dyakin; Adam Boga 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB

## Abstract The cerebral deposition of amyloid β‐peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In

Measurement of progression in Alzheimer'
Measurement of progression in Alzheimer's disease: a clinician's perspective
✍ Douglas J. Gelb 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

Patients with Alzheimer's disease (AD) and their families must confront two fundamental truths. First, AD is a uniformly progressive disease that ultimately results in debilitating cognitive impairment. Second, although there is now evidence that some medications may produce transient improvement or

Predominance of neuronal mRNAs in indivi
Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques
✍ Stephen D. Ginsberg; Peter B. Crino; Scott E. Hemby; Jeremy A. Weingarten; Virgi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 906 KB

The sequestration of RNA in Alzheimer's disease (AD) senile plaques (SPs) and the production of intraneuronal amyloid-␤ peptides (A␤) prompted analysis of the mRNA profile in single immunocytochemically identified SPs in sections of AD hippocampus. By using amplified RNA expression profiling, polyme

Passive staining: A novel ex vivo MRI pr
Passive staining: A novel ex vivo MRI protocol to detect amyloid deposits in mouse models of Alzheimer's disease
✍ Marc Dhenain; Benoît Delatour; Christine Walczak; Andreas Volk 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 470 KB

## Abstract Amyloid plaques are one of the hallmarks of Alzheimer's disease (AD). This study evaluated a novel μMRI strategy based on “passive staining” of brain samples by gadoteric acid. The protocol was tested at 4.7T on control animals and APP/PS1 mice modeling AD lesions. T~1~ was strongly dec